Sonya Weigle - Marinus Pharmaceuticals Human Relations
| MRNS Stock | USD 0.32 0.01 3.03% |
Executive
Sonya Weigle is Human Relations of Marinus Pharmaceuticals
| Address | 5 Radnor Corporate Center, Radnor, PA, United States, 19087 |
| Phone | 484 801 4670 |
| Web | https://marinuspharma.com |
Marinus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5775) % which means that it has lost $0.5775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.8655) %, meaning that it created substantial loss on money invested by shareholders. Marinus Pharmaceuticals' management efficiency ratios could be used to measure how well Marinus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.87 in 2024. Return On Capital Employed is likely to drop to -1.06 in 2024. At this time, Marinus Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 9.2 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 778 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lora Pike | Ovid Therapeutics | N/A | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| Andrew McKibben | Mirum Pharmaceuticals | N/A | |
| Vinita Kumar | Mirum Pharmaceuticals | N/A | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| Jiang JD | Connect Biopharma Holdings | N/A | |
| Dr Esq | Enliven Therapeutics | 47 | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Michael Morneau | Viking Therapeutics | 59 | |
| John Moore | Edgewise Therapeutics | 60 | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Kianoush Motesharei | Madrigal Pharmaceuticals | ||
| MBA JD | Ovid Therapeutics | 58 | |
| Carole Huntsman | Madrigal Pharmaceuticals | 59 | |
| Michael Carulli | Pmv Pharmaceuticals | 50 | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| Manoj MD | Ovid Therapeutics | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Pamela Vig | Mirum Pharmaceuticals | 53 | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
Management Performance
| Return On Equity | -29.87 | ||||
| Return On Asset | -0.58 |
Marinus Pharmaceuticals Leadership Team
Elected by the shareholders, the Marinus Pharmaceuticals' board of directors comprises two types of representatives: Marinus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Marinus. The board's role is to monitor Marinus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Marinus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Marinus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA CMA, CFO Treasurer | ||
| Christina Shafer, Chief Officer | ||
| Joseph MD, Chief Officer | ||
| Thomas Lyons, Chief Officer | ||
| Sasha Ellis, VP Relations | ||
| Lisa Lejuwaan, VP Sales | ||
| Dayong Li, Senior Biometrics | ||
| Kimberly PharmD, Chief Officer | ||
| David Czekai, Manufacturing Chemistry | ||
| Molly Cameron, Director Relations | ||
| J Esq, General VP | ||
| Sonya Weigle, Human Relations | ||
| Scott MD, President CEO | ||
| Martha Manning, Gen VP | ||
| Alex Aimetti, Chief Officer | ||
| Mark Paternoster, Senior Development | ||
| PharmD PharmD, VP Assurance |
Marinus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Marinus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -29.87 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (3.76) % | ||||
| Current Valuation | 31.74 M | ||||
| Shares Outstanding | 55.19 M | ||||
| Shares Owned By Insiders | 10.94 % | ||||
| Shares Owned By Institutions | 83.03 % | ||||
| Number Of Shares Shorted | 5.66 M | ||||
| Price To Earning | (4.80) X | ||||
| Price To Book | 3.17 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.